Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell Carcinoma.

[1]  E. V. Van Allen,et al.  Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups , 2016, Cancer Immunology Research.

[2]  Rajiv Kumar,et al.  TERT promoter mutations in melanoma render TERT expression dependent on MAPK pathway activation , 2016, Oncotarget.

[3]  K. Kinzler,et al.  High prevalence of TERT promoter mutations in primary squamous cell carcinoma of the urinary bladder , 2016, Modern Pathology.

[4]  Jun S. Song,et al.  Understanding TERT Promoter Mutations: A Common Path to Immortality , 2016, Molecular Cancer Research.

[5]  M. Xing,et al.  BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients , 2016, Oncotarget.

[6]  Jian Hu,et al.  Clinical Characteristics and Prognostic Significance of TERT Promoter Mutations in Cancer: A Cohort Study and a Meta-Analysis , 2016, PloS one.

[7]  W. Hahn,et al.  TERT promoter mutations and monoallelic activation of TERT in cancer , 2015, Oncogenesis.

[8]  Z. Cai,et al.  The C228T mutation of TERT promoter frequently occurs in bladder cancer stem cells and contributes to tumorigenesis of bladder cancer , 2015, Oncotarget.

[9]  J. Boyle,et al.  Cancer-associated TERT promoter mutations abrogate telomerase silencing , 2015, eLife.

[10]  K. Hemminki,et al.  TERT promoter mutations in clear cell renal cell carcinoma , 2015, International journal of cancer.

[11]  Donavan T. Cheng,et al.  Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. , 2015, The Journal of molecular diagnostics : JMD.

[12]  Wei Wang,et al.  Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation. , 2015, European journal of cancer.

[13]  K. Hemminki,et al.  TERT promoter mutations and telomere length in adult malignant gliomas and recurrences , 2015, Oncotarget.

[14]  James C. Costello,et al.  TERT promoter mutations and telomerase reactivation in urothelial cancer , 2015, Science.

[15]  Y. Cao,et al.  Ets-1 as an early response gene against hypoxia-induced apoptosis in pancreatic β-cells , 2015, Cell Death and Disease.

[16]  J. Schramm,et al.  TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas. , 2015, Neuro-oncology.

[17]  Lawrence A. Donehower,et al.  The somatic genomic landscape of chromophobe renal cell carcinoma. , 2014, Cancer cell.

[18]  G. Ciriello,et al.  Impact of recurrent copy number alterations and cancer gene mutations on the predictive accuracy of prognostic models in clear cell renal cell carcinoma. , 2014, The Journal of urology.

[19]  C. Liu,et al.  TERT promoter mutations in renal cell carcinomas and upper tract urothelial carcinomas , 2014, Oncotarget.

[20]  G. Aubert.  Telomere dynamics and aging. , 2014, Progress in molecular biology and translational science.

[21]  D. Schadendorf,et al.  TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism , 2013, Proceedings of the National Academy of Sciences.

[22]  Lars Egevad,et al.  The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia , 2013, The American journal of surgical pathology.

[23]  Miguel Melo,et al.  Frequency of TERT promoter mutations in human cancers , 2013, Nature Communications.

[24]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of clear cell renal cell carcinoma , 2013, Nature.

[25]  The Cancer Genome Atlas Research Network.  COMPREHENSIVE MOLECULAR CHARACTERIZATION OF CLEAR CELL RENAL CELL CARCINOMA , 2013, Nature.

[26]  C. Sander,et al.  Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators BAP1 and SETD2: A Report by MSKCC and the KIRC TCGA Research Network , 2013, Clinical Cancer Research.

[27]  Lynda Chin,et al.  Highly Recurrent TERT Promoter Mutations in Human Melanoma , 2013, Science.

[28]  H. Yee,et al.  Regulation of hypoxia-inducible genes by ETS1 transcription factor. , 2008, Carcinogenesis.

[29]  E. Blackburn,et al.  Tracking telomerase , 2004, Cell.

[30]  J. Cheville,et al.  An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. , 2002, The Journal of urology.

[31]  J. Steitz,et al.  Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. , 1992, The EMBO journal.